152 related articles for article (PubMed ID: 16736729)
21. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
22. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
[TBL] [Abstract][Full Text] [Related]
23. Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
Giovannini MG; Bartolini L; Bacciottini L; Greco L; Blandina P
Behav Brain Res; 1999 Oct; 104(1-2):147-55. PubMed ID: 11125734
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
[TBL] [Abstract][Full Text] [Related]
25. Sch 50971, an orally active histamine H3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig.
McLeod RL; Aslanian R; del Prado M; Duffy R; Egan RW; Kreutner W; McQuade R; Hey JA
J Pharmacol Exp Ther; 1998 Oct; 287(1):43-50. PubMed ID: 9765320
[TBL] [Abstract][Full Text] [Related]
26. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.
Goadsby PJ; Ferrari MD; Olesen J; Stovner LJ; Senard JM; Jackson NC; Poole PH
Neurology; 2000 Jan; 54(1):156-63. PubMed ID: 10636142
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
28. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group.
Visser WH; Ferrari MD; Bayliss EM; Ludlow S; Pilgrim AJ
Cephalalgia; 1992 Oct; 12(5):308-13. PubMed ID: 1330318
[TBL] [Abstract][Full Text] [Related]
29. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
30. The H3 receptor is involved in cholecystokinin inhibition of food intake in rats.
Attoub S; Moizo L; Sobhani I; Laigneau JP; Lewin MJ; Bado A
Life Sci; 2001 Jun; 69(4):469-78. PubMed ID: 11459437
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
Cady RK; Mathew N; Diener HC; Hu P; Haas M; Novak GP;
Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
[TBL] [Abstract][Full Text] [Related]
32. N alpha-methylhistamine inhibits intestinal transit in mice by central histamine H1 receptor activation.
Oishi R; Adachi N; Saeki K
Eur J Pharmacol; 1993 Jun; 237(2-3):155-9. PubMed ID: 8103457
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
[TBL] [Abstract][Full Text] [Related]
34. Histamine and migraine revisited: mechanisms and possible drug targets.
Worm J; Falkenberg K; Olesen J
J Headache Pain; 2019 Mar; 20(1):30. PubMed ID: 30909864
[TBL] [Abstract][Full Text] [Related]
35. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
36. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
37. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
38. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group.
Diener HC; Föh M; Iaccarino C; Wessely P; Isler H; Strenge H; Fischer M; Wedekind W; Taneri Z
Cephalalgia; 1996 Oct; 16(6):441-7. PubMed ID: 8902255
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography.
Mezzomo K; Cumming P; Minuzzi L
Eur J Pharmacol; 2007 Jun; 564(1-3):75-9. PubMed ID: 17350614
[TBL] [Abstract][Full Text] [Related]
40. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
